These vaccine candidates combine the flu vaccine with the Novavax COVID-19 vaccine, offering a potential single shot to address both diseases.
The designation was granted to expedite the development of vaccines that could help reduce the health burdens of flu and COVID-19, especially for groups that are at higher risk of severe outcomes such as prolonged hospital stays and long-term complications.
The first combination candidate combines Fluzone High-Dose, a high-dose flu vaccine, with Novavax’s COVID-19 vaccine. The second candidate uses Flublok, a recombinant flu vaccine paired with the same Novavax COVID-19 vaccine.
Both flu vaccines have been shown to be more effective than standard-dose flu vaccines in preventing infections and reducing hospitalizations in older adults. The Novavax COVID-19 vaccine has also demonstrated good safety and efficacy profiles in previous clinical trials, according to the release.
Sanofi, which is developing the vaccines, has launched phase ½ clinical trials to evaluate the safety and immune responses to the combination shots. The trials aim to assess whether combining these vaccines can maintain their efficacy while simplifying vaccination schedules, potentially improving uptake among older adults.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
